Drugs / KOS-1584
KOS-1584
also known as
(e)-9,10-dehydroepothilone d · (e)-9,10-didehydroepothilone d · 9,10-trans-dehydroepothilone d · Dehydelone · R-1645
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00651508 | Apr → Oct 2008 | non-small cell lung carcinoma | Bristol-Myers Squibb | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KOS-1584 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00651508 ↗ |
| Known as | (e)-9,10-dehydroepothilone d | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297296 ↗ |
| Known as | (e)-9,10-didehydroepothilone d | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297296 ↗ |
| Known as | 9,10-trans-dehydroepothilone d | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297296 ↗ |
| Known as | Dehydelone | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297296 ↗ |
| Known as | R-1645 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297296 ↗ |
| Modality | Small molecule | — CHEMBL4297296 ↗ |
| Route | Intravenous | “25 mg/m2, IV (in the vein) on day 1 and 8 of each 21 day cycle” NCT00651508 ↗ |